Investing

Enact : ACT

ACT

Stock Data

$40.27

$0.53 (1.33%)

Asset Type

Common Stock

Exchange

NASDAQ

Currency

USD

Country

USA

Sector

FINANCIAL SERVICES

Industry

INSURANCE - SPECIALTY

Enact Holdings, Inc. operates as a private mortgage insurance company in the United States. The company engages in writing and assuming residential mortgage guaranty insurance. It also offers private mortgage insurance products primarily insuring prime-based, individually underwritten residential mortgage loans; and contract underwriting services for mortgage lenders. It primarily serves residential mortgage loan originators. The company was formerly known as Genworth Mortgage Holdings, Inc. and changed its name to Enact Holdings, Inc. in May 2021. Enact Holdings, Inc. was founded in 1981 and is headquartered in Raleigh, North Carolina. Enact Holdings, Inc. operates as a subsidiary of Genworth Holdings Inc.

All Enact Articles

29 Articles

Paul Ausick | Sep 2, 2020 at 1:46 PM EDT

US-Focused Cannabis ETF Debuts

A new ETF that includes only U.S. firms operating in the legal cannabis market made its first appearance on Wednesday.

Chris Lange | Dec 27, 2019 at 11:15 AM EST

Is This a Buying Opportunity for Cannabis ETFs Going Into 2020?

Many investors are focused on getting the jump on the cannabis industry, but they aren’t alone. With this increased speculation,…

Paul Ausick | May 14, 2019 at 9:36 AM EDT

5 ETFs Targeting Sinners

The ETF universe includes a variety of funds that allow investors to share in the spoils of legal gambling, smoking…

Chris Lange | May 9, 2019 at 11:01 AM EDT

Wall Street Has a New Strategy for Legal Marijuana – Whenever That Happens

With evolving societal and regulatory landscapes, the upside potential of cannabis as a new investment strategy has emerged. Investors can…

Jon C. Ogg | Oct 29, 2015 at 11:05 AM EDT

What a Combined Allergan and Pfizer Might Actually Look Like

Allergan has issued a press release that confirms some of the rumors floating in the market that it has been…

Chris Lange | May 24, 2015 at 9:15 AM EDT

Large Companies With Fastest Revenue and Earnings Growth in 2015

S&P Capital IQ released a report regarding the performance of companies in terms of earnings and revenue.

Chris Lange | Mar 17, 2015 at 9:40 AM EDT

American Airlines Replaces Allergan in S&P 500

American Airlines will be the newest addition to the S&P 500, taking the place of Allergan.

Lee Jackson | Mar 17, 2015 at 8:35 AM EDT

6 Stocks Will See Massive Buying and Selling on S&P Quarterly Rebalance

All indexes rebalance on a quarterly basis. 24/7 Wall St. screened a recent Jefferies report for the stocks that will…

Chris Lange | Mar 16, 2015 at 9:10 AM EDT

As Valeant Ups Salix Buyout, Will Endo Come Back?

Salix Pharmaceuticals and Valeant Pharmaceuticals have announced that they had entered into an agreement on their plan to merge based…

Lee Jackson | Mar 4, 2015 at 10:10 AM EST

UBS Makes Big Changes to Equity Focus List For March

A new report from UBS shows some serious changes made to the firm's Equity Focus list for March.

Paul Ausick | Mar 3, 2015 at 11:45 AM EST

Is the Actavis $21 Billion Bond Sale Just the First?

Actavis launched second-largest ever bond sale Monday to raise $21 billion to pay for its acquisition of Allergan.

Lee Jackson | Feb 17, 2015 at 8:25 AM EST

UBS Quality Growth at a Reasonable Price Stocks Beating the S&P 500

The UBS CIO Wealth Management team makes a good case that investors should consider the stocks in the firm's Quality…

Chris Lange | Dec 19, 2014 at 2:58 PM EST

Merrill Lynch’s Top Health Care Stock Picks for 2015

24/7 Wall St. has compiled a list health care stocks that Merrill Lynch expects to be top performers in 2015.

Paul Ausick | Dec 18, 2014 at 12:00 PM EST

9 Big Stocks That Doubled in 2014

Here is a look at the top performers for 2014, nine stocks that have doubled and have a current market…

Jon C. Ogg | Dec 10, 2014 at 10:35 AM EST

What a Generic Celebrex Means for Pfizer and for Actavis

While this was generally a known event coming down the pipe, arthritis drug Celebrex now has a generic competitor in…